Cardiovascular Diseases: Where Do We Stand with Human-Derived Stem Cells?
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 3134
Special Issue Editors
Interests: cardiovascular physiology; cardiomyocytes; hiPSC-derived cardiomyocytes; patch clamp; GPCR signaling
Special Issue Information
Dear Colleagues,
The treatment of cardiac and vascular outcomes is becoming an intriguing global target due to the high morbidity and mortality related to these pathological conditions.
In addition to drug treatments that have produced significant results in preventing and treating cardiovascular diseases, the personalized medicine approach seems to be a great opportunity for clinical intervention.
In this scenario, human induced pluripotent stem cells (hiPSC) represent a possible tool to be used in a two-way approach: first, in regenerative medicine, particularly those conditions related to the loss of heart function, and second, as a cellular model able to be used instead of animals, which are important models for drug study and application, but, unfortunately, still far from humans.
This Special Issue aims to present discoveries in the differentiation procedures, function, and physiological and metabolic characterization of hiPSC-derived cells, focusing on their use in treating cardiovascular diseases or drug screening.
Original research papers, critical up-to-date articles, and reviews on the potential use of hiPSC in cardiac and vascular pathologies are welcome.
Dr. Daniela Malan
Dr. Giulia Querio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hiPSC
- regenerative medicine
- personalized medicine
- cardiovascular disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
